A Review of Modeling Approaches to Predict Drug Response in Clinical Oncology

被引:13
作者
Park, Kyungsoo [1 ]
机构
[1] Yonsei Univ, Coll Med, Dept Pharmacol, 50-1 Yonsei Ro, Seoul 03722, South Korea
关键词
Model-based approaches; drug development; drug treatment; chemotherapeutic drug; PROGRESSION-FREE SURVIVAL; SURROGATE END-POINT; PHARMACODYNAMIC MODEL; TUMOR-GROWTH; DISEASE PROGRESSION; CANCER-PATIENTS; CHEMOTHERAPY; SIZE; TIME; PHARMACOKINETICS;
D O I
10.3349/ymj.2017.58.1.1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Model-based approaches have emerged as important tools for quantitatively understanding temporal relationships between drug dose, concentration, and effect over the course of treatment, and have now become central to optimal drug development and tailored drug treatment. In oncology, the therapeutic index of a chemotherapeutic drug is typically narrow and a full dose-response relationship is not available, often because of treatment failure. Noting the benefits of model-based approaches and the low therapeutic index of oncology drugs, in recent years, modeling approaches have been increasingly used to streamline oncologic drug development through early identification and quantification of dose-response relationships. With this background, this report reviews publications that used model-based approaches to evaluate drug treatment outcome variables in oncology therapeutics, ranging from tumor size dynamics to tumor/biomarker time courses and survival response.
引用
收藏
页码:1 / 8
页数:8
相关论文
共 43 条
  • [1] Development and evaluation of a population pharmacokinetic-pharmacodynamic model of darbepoetin alfa in patients with nonmyeloid malignancies undergoing multicycle chemotherapy[J]. Agoram, Balaji;Heatherington, Anne C.;Gastonguay, Marc R. AAPS JOURNAL, 2006(03)
  • [2] Population pharmacokinetic-pharmacodynamic modelling in oncology: a tool for predicting clinical response[J]. Bender, Brendan C.;Schindler, Emilie;Friberg, Lena E. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2015(01)
  • [3] Modeling tumor growth kinetics after treatment with pazopanib or placebo in patients with renal cell carcinoma[J]. Bonate, Peter L.;Suttle, A. Benjamin. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2013(01)
  • [4] On the Use of Change in Tumor Size to Predict Survival in Clinical Oncology Studies: Toward a New Paradigm to Design and Evaluate Phase II Studies[J]. Bruno, R.;Claret, L. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2009(02)
  • [5] A Population Pharmacodynamic Model for Lactate Dehydrogenase and Neuron Specific Enolase to Predict Tumor Progression in Small Cell Lung Cancer Patients[J]. Buil-Bruna, Nuria;Lopez-Picazo, Jose-Maria;Moreno-Jimenez, Marta;Martin-Algarra, Salvador;Ribba, Benjamin;Troconiz, Inaki F. AAPS JOURNAL, 2014(03)
  • [6] Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer[J]. Burzykowski, Tomasz;Buyse, Marc;Piccart-Gebhart, Martine J.;Sledge, George;Carmichael, James;Lueck, Hans-Joachim;Mackey, John R.;Nabholtz, Jean-Marc;Paridaens, Robert;Biganzoli, Laura;Jassem, Jacek;Bontenbal, Marijke;Bonneterre, Jacques;Chan, Stephen;Basaran, Gul Atalay;Therasse, Patrick. JOURNAL OF CLINICAL ONCOLOGY, 2008(12)
  • [7] Evaluation of Tumor-Size Response Metrics to Predict Overall Survival in Western and Chinese Patients With First-Line Metastatic Colorectal Cancer[J]. Claret, Laurent;Gupta, Manish;Han, Kelong;Joshi, Amita;Sarapa, Nenad;He, Jing;Powell, Bob;Bruno, Rene. JOURNAL OF CLINICAL ONCOLOGY, 2013(17)
  • [8] Development of a modeling framework to simulate efficacy endpoints for motesanib in patients with thyroid cancer[J]. Claret, Laurent;Lu, Jian-Feng;Sun, Yu-Nien;Bruno, Rene. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2010(06)
  • [9] Model-Based Prediction of Phase III Overall Survival in Colorectal Cancer on the Basis of Phase II Tumor Dynamics[J]. Claret, Laurent;Girard, Pascal;Hoff, Paulo M.;Van Cutsem, Eric;Zuideveld, Klaas P.;Jorga, Karin;Fagerberg, Jan;Bruno, Rene. JOURNAL OF CLINICAL ONCOLOGY, 2009(25)
  • [10] Nonlinear Mixed-Effect Models for Prostate-Specific Antigen Kinetics and Link with Survival in the Context of Metastatic Prostate Cancer: a Comparison by Simulation of Two-Stage and Joint Approaches[J]. Desmee, Solene;Mentre, France;Veyrat-Follete, Christine;Guedj, Jeremie. AAPS JOURNAL, 2015(03)